Moreover, etomoxir treatment would reverse the protective effects of FABP3 on cardiac hypertrophy and upregulated the mRNA expression of Bnp and Anp (Supplementary Figure 5F). The gene discussed is FABP3; the disease is cardiac hypertrophy.